Radiotherapy in the management of Kaposi's sarcoma : Comparison of 8 Gy versus 6 Gy

• Published in: Journal of the National Medical Association 2006-07, Vol.98 (7), p.1136-1139
• Main Authors: YILDIZ, Ferah, GENC, Mine, AKYUREK, Serap, CENGIZ, Mustafa, OZYAR, Enis, SELEK, Ugur, ATAHAN, I. Lale
• Format: Article
• Language: English
• Subjects: Adolescent; Adult; Aged; Aged, 80 and over; Biological and medical sciences; Dermatology; Disease-Free Survival; Female; General aspects; Hodgkin Disease - immunology; Hospitals, Teaching; Humans; Immunocompromised Host; Male; Medical sciences; Middle Aged; Prospective Studies; Radiotherapy Dosage; Sarcoma, Kaposi - diet therapy; Sarcoma, Kaposi - radiotherapy; Treatment Outcome; Tumors of the skin and soft tissue. Premalignant lesions; Turkey
• ISSN: 0027-9684; 1943-4693

To evaluate prospectively the efficacy of a single fraction of high-dose radiotherapy in patients with Kaposi's sarcoma. Between 1994 and 2004, 47 patients with Kaposi's sarcoma were treated at Hacettepe University, Department of Radiation Oncology. Thirteen (28%) patients received chemotherapy before radiotherapy and were referred due to recurrent or progressive disease or intolerance to chemotherapy. All lesions were treated locally with a 2-3-cm safety margin with 4-6-MeV electron beams. Radiotherapy consisted of a single fraction of 8 Gy in the first four years and 6 Gy thereafter. The male:female ratio was 4:1. The median age was 61 years (range 18-87). Eight out of 47 patients (17%) had an underlying immunocompromised state, and one had a previous diagnosis of Hodgkin's disease. Of 203 fields treated, 51 and 152 fields were treated with 8 Gy and 6 Gy, respectively. Overall response rates (RR) at 12 months for 8- and 6 Gy were 93% and 86%, which were not statistically different. However, the difference between complete RRs at 12 months (93% and 60% for 8 Gy and 6 Gy respectively) was significant (p